Objective: To define the optimal treatment for women with stage III or locally advanced breast cancer (LABC).
can be treated with taxane chemotherapy or can proceed directly to irradiation followed by modified radical mastectomy, if feasible. Systemic therapy: hormonal therapy Operable and inoperable tumours • Tamoxifen for 5 years should be recommended to pre-and postmenopausal women whose tumours are hormone responsive.
Locoregional management
Operable tumours • Patients with stage IIIA disease should receive both modified radical mastectomy (MRM) and locoregional radiotherapy if feasible. They may be managed with MRM followed by chemotherapy and locoregional radiotherapy, or chemotherapy first followed by MRM and locoregional radiotherapy. Breast-conserving surgery is currently not a standard approach.
• Locoregional radiotherapy should be delivered to the chest wall and to the supraclavicular and axillary nodes. L ocally advanced breast cancer (LABC) occurs relatively infrequently, but it poses a significant clinical challenge. LABC refers to large breast tumours (> 5 cm in diameter) associated with either skin or chest-wall involvement or with fixed (matted) axillary lymph nodes or with disease spread to the ipsilateral internal mammary or supraclavicular nodes. 1 Inflammatory breast cancer, which manifests as a red swollen breast, is considered a type of LABC. The TumourNode-Metastasis (TNM) system is used to classify breast cancer into stages (Table 1) . 1 According to this system, LABC is stage III.
During the last 60 years, the management of LABC has evolved considerably. Initially, patients with LABC were treated with radical mastectomy. 2 Based on the disappointing results of surgery and radiotherapy [2] [3] [4] in patients with LABC, and the early promising results of adjuvant systemic therapy in women with axillary node-positive breast cancer, 5, 6 systemic therapy was subsequently incorporated along with surgery and radiotherapy into the management of patients with LABC, termed "combined modality therapy." Even with such combined modality therapy, the long-term survival rate is approximately 50% among patients with LABC. 7 The focus of this guideline is to determine the optimal therapeutic approach for patients who present with LABC.
Methods
We conducted a systematic review of the English-language literature retrieved from MEDLINE (1984 to June 2002) and CANCERLIT (1983 to June 2002). Search terms used were "breast neoplasms," "locally advanced breast cancer," "stage III breast cancer," "drug therapy," "neo-adjuvant," "primary systemic therapy," "radiotherapy or irradiation," "surgery," "randomized trials" and "high-dose therapy." A nonsystematic review of the literature was continued through December 2003. Additional data were identified by reviewing references in retrieved reports and by monitoring major conferences on breast cancer. The quality of the evidence on which conclusions are based is categorized into 5 levels. 8 The main outcomes considered are locoregional control (defined as freedom from recurrence in the breast, chest wall or regional lymph nodes), disease-free survival (DFS; defined as survival free of breast cancer recurrence) and overall survival (OS).
We were faced with a number of challenges when trying to synthesize the results of the studies from the review of the literature. These included:
• Many studies were case series (levels IV and V evidence).
• The studies included different populations of patients with differing prognoses; for example, some studies included patients with inflammatory breast cancer whereas other studies did not.
• In studies evaluating systemic therapies, local therapy (surgery/radiotherapy) was often not standardized.
• The TNM tumour-staging system changed, in that tumours associated with ipsilateral supraclavicular nodal involvement that were initially considered LABC were considered metastatic breast cancer between 1987 and 2002 and are now considered LABC again.
1
• The randomized trials that were available were old, had small patient numbers and used systemic therapy combinations that are often not used today. We developed this guideline using a framework based on the operability of the tumour. The current TNM staging system, which is based on clinical characteristics of the primary tumour and regional lymph nodes, is used to help determine operability (Table 1) . 1 Large operable tumours include stage IIB and IIIA disease. Nonoperable tumours include stage IIIB or stage IIIC disease. Patients with ipsilateral supraclavicular lymph-node involvement as their sole site of metastases have in the past been classified as having stage IV breast cancer, but they have a better prognosis than patients with other sites of metastases and are included in the category of inoperable LABC (stage IIIC disease) within this guideline. 1, 9, 10 Recommendations (including evidence and rationale)
• The management of LABC requires a combined modality treatment approach involving surgery, radiotherapy and systemic therapy.
The clinical management of LABC is complex and should be tailored to the individual patient. Frequently, surgery, radiotherapy and systemic therapy (chemotherapy, hormone therapy) are used. A multidisciplinary approach 
IV
Any T Any N M 1 *Tumour status: Tis = carcinoma in situ; T 0 = no evidence of primary tumour; T 1 = tumour ≤ 2 cm in greatest dimension; T 2 = tumour > 2 cm but not > 5 cm in greatest dimension;
T 3 = tumour > 5 cm in greatest dimension; T 4 = tumour of any size with chest-wall extension, ulceration, peau d'orange or inflammatory breast cancer. †Node status: N 0 = no regional lymph-node metastasis; N 1 = metastasis in movable ipsilateral axillary lymph node(s); N 2 = metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph-node metastasis; N 3 = metastasis in ipsilateral internal mammary lymph node(s) or in ipsilateral supraclavicular lymph node(s). ‡Metastasis status: M 0 = no distant metastasis; M 1 = distant metastasis.
to LABC is recommended in which treatment is based on the combined opinions of a surgeon, radiation oncologist and medical oncologist. The initial management of LABC requires histological confirmation (e.g., core biopsy, incisional biopsy or skin biopsy) for diagnosis and for determination of hormone receptor and HER-2 neu oncogene status. Cytological evaluation by fine-needle aspiration is insufficient.
Systemic therapy: chemotherapy Operable tumours
• Patients with operable stage IIIA disease should be offered chemotherapy. They should receive adjuvant chemotherapy following surgery, or primary chemotherapy followed by locoregional management.
Patients with stage IIIA breast cancer have potentially operable tumours. There are 2 approaches for treating these patients. The first is modified radical mastectomy (MRM) followed by adjuvant systemic therapy and radiotherapy, and the second is preoperative chemotherapy followed by surgery and radiotherapy.
Surgery followed by adjuvant chemotherapy
There have been only 2 randomized clinical trials of adjuvant chemotherapy exclusively in patients with stage III disease ( Table 2) . 11, 12 One of these studies 11 reported a benefit with chemotherapy (level I evidence). The metaanalysis of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 5, 6 included a subset of patients with large operable tumours. Overall, all patients benefited from adjuvant systemic chemotherapy regardless of tumour size (level I evidence). Therefore, it is reasonable to extrapolate the overall conclusions of the meta-analysis to patients with operable stage IIIA disease.
Primary chemotherapy followed by surgery
A number of case series have reported on preoperative chemotherapy in patients with operable stage IIIA breast cancer (level IV evidence). [13] [14] [15] [16] Table 3 summarizes one retrospective study and the randomized trials that compared preoperative and postoperative chemotherapy. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] The primary purpose of these studies was to determine whether preoperative chemotherapy, compared with postoperative chemotherapy, improved DFS and OS. These studies involved patients mainly with stage I or stage II disease and included a small proportion of women with tumours greater than 5 cm in diameter. No difference in DFS and OS was detected between the pre- operative and postoperative chemotherapy groups (level II evidence). Preoperative chemotherapy often caused shrinkage of the tumour and permitted the performance of breast-conserving surgery (BCS) when a mastectomy was originally planned. [17] [18] [19] [20] [21] [22] [23] [24] [25] However, results from 2 trials suggested that patients whose tumours were down-staged so that BCS could be performed when it was not initially planned were at higher risk of local recurrence 19 and had worse survival. 20 Choice of chemotherapy have addressed the issue of the type of chemotherapy to be used. 11, 26, 27 The number of patients in these trials was small. Two trials showed improved DFS with anthracyclinebased chemotherapy over no chemotherapy (level I evidence) 11 and over a CMF-vincristine-prednisone regimen (level II evidence). 27 A third trial showed no difference in DFS or OS between CMF and a CMF-epirubicinvincristine regimen (level II evidence) ( Table 2) . 26 Hence, recommendations concerning the type of chemotherapy regimens to be used in stage IIIA disease are based on extrapolation from trials in women with metastatic breast cancer and node-positive breast cancer.
Results of randomized trials involving women with metastatic breast cancer have shown a superior response rate and prolonged DFS with anthracycline-containing chemotherapy regimens than with CMF. 28, 29 Randomized trials have confirmed the superiority of anthracycline-containing regimens such as CEF and CAF over conventional CMF in women with node-negative and node-positive breast cancer. [30] [31] [32] In contrast, in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-15 trial, 4 cycles of AC chemotherapy was equivalent to 6 months of CMF. 33 In the most recent EBCTCG overview, 5 there was a statistically significant improvement in survival with anthracyclinebased chemotherapy compared with CMF in early stage breast cancer. Although there are limitations to crossstudy comparisons, it is reasonable to consider that 4 cycles of AC, although equivalent to 6 months of CMF, 33 is probably inferior to 6 cycles of anthracycline-containing drug regimens such as FAC, 16 CAF, 28,30 CEF 32 and FEC. 34 In women who cannot receive anthracyclines because of underlying cardiac disease, CMF chemotherapy can be considered. Six cycles of chemotherapy should be administered. This is based on the trials of adjuvant chemotherapy that showed that 6 cycles of CAF or CEF was superior to 6 cycles of CMF 30, 32 and that 6 cycles of FEC was superior to 3 cycles of FEC. 35 In a multicentre trial, 448 women with LABC were randomly allocated to receive either CEF, or EC plus GCSF (Table 3) . 7 At a median follow-up of 5.5 years, no difference in survival was detected between the 2 groups (53% and 51% respectively; level II evidence).
The role of taxanes in LABC and as preoperative chemotherapy in women with early breast cancer is currently under investigation. Studies involving women with metastatic breast cancer indicate that taxanes can cause significant tumour regression and improvement in symptoms in patients with anthracycline-resistant disease. 36, 37 Taxane-containing regimens have been evaluated in randomized trials involving patients with axillary node-positive breast cancer. Compared with AC, AC followed by paclitaxel was associated with improved DFS in 2 trials 38, 39 and with improved OS in 1 trial. 38 A recent trial suggested that AC administered every 2 weeks followed by paclitaxel every 2 weeks (dose dense chemotherapy) was associated with improved DFS compared with the usual AC followed by paclitaxel, both administered every 3 weeks. 40 Another recently reported trial involving women with node-positive breast cancer showed that, compared with FAC, the chemotherapy regimen TAC improved DFS and OS. 41 In a trial of FAC versus paclitaxel, both administered preoperatively, no difference was detected in clinical or pathologic response rate and DFS (Table 3) . 42 Results from 2 studies suggested that the addition of a taxane sequentially to an anthracyclinebased regimen can improve clinical and pathologic response (Table 3) . [43] [44] [45] Currently, there are insufficient data to make definitive recommendations concerning the use of taxane-containing regimens in LABC. However, this is an evolving area of investigation. Management of LABC with systemic therapy remains an area for further research, and randomized studies are needed to identify optimal strategies. Participation in clinical trials is encouraged. [See the discussion of chemotherapy in the section "operable tumours."] The results of trials of chemotherapy in women with metastatic breast cancer and axillary nodepositive breast cancer have demonstrated the superiority of anthracycline-containing combination chemotherapy over CMF. [28] [29] [30] [31] [32] On the basis of this evidence, when chemotherapy is used for treating stage IIIB or IIIC breast cancer, an anthracycline-containing regimen should be used if there are no contraindications to its use. A regimen of FAC, CAF, CEF or FEC is preferred. 16, 30, 32, 34 An adequate dose intensity and total dose of anthracycline should be used. 34, 46 CMF chemotherapy can be used in women who cannot receive anthracycline-containing chemotherapy because of underlying heart disease. The role of taxanes is currently under investigation, and no recommendations can be made at present for the incorporation of taxanes in primary chemotherapy for inoperable LABC.
There is currently no evidence to support the use of high-dose chemotherapy with stem cell support for this group of patients, as the randomized trials involving women with metastatic breast cancer and breast cancer with extensive nodal involvement have demonstrated no difference in survival between high-dose chemotherapy and standard-dose chemotherapy (level II evidence). Patients with stage III disease who are treated with primary chemotherapy need to be followed carefully for evidence of response. Multivariate analyses in several studies [17] [18] [19] 49, 50 have shown that the primary tumour response is correlated with patient outcome and that patients who have pathological evidence of a complete response following primary therapy have a superior DFS and OS compared with those who do not have such a response (level III evidence). Clinical response is seen in about 80% of patients who receive primary chemotherapy. To ascertain response, at least 2-3 cycles of chemotherapy should be administered.
The treatment of patients with LABC whose tumours do not respond to anthracycline-containing chemotherapy is unclear. It is reasonable to try taxane chemotherapy [42] [43] [44] [45] or to proceed directly to locoregional therapy including irradiation and MRM, if possible. Patients with stage IIIB or IIIC disease who do have a clinical response to primary chemotherapy should receive ongoing treatment until the manifested response clearly plateaus or to a maximum of 6 cycles, whichever comes first. The threshold for anthracycline-associated cardiac toxicity should not be exceeded. The optimal duration of primary chemotherapy is unclear. However, the results of studies involving women with node-positive breast cancer who received adjuvant chemotherapy showed that a regimen of 6 cycles of CMF was superior to that of 3 cycles of CMF 51 and that a regimen of 6 cycles of FEC was superior to that of 3 cycles of FEC. 35 It is unclear whether additional chemotherapy should be administered following primary chemotherapy and definitive locoregional therapy. This has been examined in several case series (level V evidence). 15, 16, 49 Systemic therapy: hormonal therapy
Operable and inoperable tumours
• Tamoxifen for 5 years should be recommended to pre-and postmenopausal women whose tumours are hormone responsive.
Following completion of chemotherapy, pre-or postmenopausal patients with LABC and hormone-responsive tumours should receive adjuvant tamoxifen therapy, 20 mg/d, for 5 years (see guideline 8). 5, 52 Tamoxifen should be started after completion of chemotherapy. 53 The aromatase inhibitor, anastrozole, has been compared with tamoxifen in postmenopausal women with early breast cancer following surgery. 54 The early results of that study showed that, compared with tamoxifen, anastrozole was associated with improved DFS and had fewer side effects. The role of aromatase inhibitors as adjuvant therapy in breast cancer is evolving. 55 The role of luteinizing hormone-releasing hormone agonists in premenopausal patients is evolving as new data emerge (see guideline 8).
Patients who are not candidates for any chemotherapy can be managed with hormonal treatment and then receive locoregional management as described below.
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Locoregional management
Operable tumours
• Patients with stage IIIA disease should receive both modified radical mastectomy (MRM) and locoregional radiotherapy if feasible. They may be managed with MRM followed by chemotherapy and locoregional radiotherapy, or chemotherapy first followed by MRM and locoregional radiotherapy. Breast-conserving surgery is currently not a standard approach.
Locally advanced breast cancer MRM (mastectomy plus a level 1 and level 2 axillary dissection) remains the standard surgical treatment for operable locally advanced disease. The role of BCS is unclear and the subject of research. Previous studies demonstrating equivalence of BCS to mastectomy were performed in patients with stage I and II disease (see guideline 3). In the trials that compared preoperative chemotherapy with chemotherapy administered postoperatively, the proportion of women with tumours greater than 5 cm in diameter ranged from 5% to 27%. Patients with operable stage III disease who desire to preserve their breast should be made aware that BCS is currently not a standard approach and is generally not recommended. There is a lack of evidence concerning breast reconstruction surgery in women with LABC. Reconstruction is generally performed after completion of chemotherapy and radiotherapy, because of the concern that postoperative complications could delay chemotherapy and radiotherapy.
In the largest study evaluating locoregional therapy, 59, 60 eligible patients with operable LABC had a mastectomy, 6 cycles of anthracycline-based chemotherapy and, if disease-free, were randomly assigned to receive radiotherapy or observation with radiotherapy at isolated sites of locoregional failure (Table 2) . Locoregional recurrences were reduced from 24% to 15% with immediate radiotherapy (level I evidence).
Two smaller randomized trials had conflicting results regarding the value of radiotherapy. These trials are summarized in Table 2 (level I evidence) 11 and Table 3 (level II  evidence) . 61 There is a large body of level I and level II evidence demonstrating that locoregional radiotherapy following mastectomy in patients with node-positive disease treated with systemic therapy is associated with not only a reduction in locoregional recurrence but also an increase in overall survival (see guideline on postmastectomy radiotherapy). In the 3 largest trials of postmastectomy radiotherapy, 12%-14% of patients had stage IIIA disease. [62] [63] [64] A meta-analysis of all trials in which patients were treated with systemic therapy also confirmed the benefit of locoregional radiotherapy in improving disease-free and overall survival. 65 In summary, the results of 2 randomized trials and data extrapolated from trials involving women with nodepositive disease support the use of locoregional radiotherapy in patients with LABC who are treated with mastectomy.
• Locoregional radiotherapy should be delivered to the chest wall and to the supraclavicular and axillary nodes. The role of internal mammary irradiation is unclear.
When locoregional radiotherapy is delivered following MRM for locally advanced disease, radiation should be de- livered to the chest wall and the supraclavicular and axillary nodes. Whether treatment to the internal mammary nodes is required is unclear. 66 In many of the studies reviewed for this guideline, the internal mammary nodes were irradiated. However, there are no studies that examined the impact of such radiotherapy. It is not unreasonable to include radiotherapy to the internal mammary nodal region, provided that this can be done without treating an excessive amount of heart or lung tissue. Locoregional radiotherapy has been associated with a modest increase in late non-breast-cancer deaths of cardiac or vascular origin. 66 The recommended dose of radiation is 50 Gy in 25 fractions or equivalent. Three small trials compared MRM alone with locoregional radiotherapy alone following chemotherapy (Table 4) . [67] [68] [69] The results of these studies suggest that both treatments are equally effective after primary chemotherapy in inoperable disease (level II evidence).
No randomized trials were found that compared mastectomy plus locoregional radiotherapy with mastectomy alone following chemotherapy, but 2 case series demonstrated that locoregional control was better if both mastectomy and radiotherapy were performed 70, 71 (level V evidence). The results of these studies and data from randomized trials in operable disease support the use of both MRM and locoregional radiotherapy in achieving optimal local control when feasible. It is unknown whether the sequence of surgery and radiotherapy makes a difference. Technical and disease factors will usually influence the order of treatments. For example, patients who have a good response to primary chemotherapy may be best managed by MRM followed by radiotherapy. Patients who remain inoperable after chemotherapy could receive radiotherapy followed by surgery, if feasible. Again, similar to operable disease, the role of BCS in this situation is unclear and is the subject of research.
The locoregional management of patients with stage IIIC disease who respond to chemotherapy is unclear. In the absence of evidence on this subgroup of patients, it is reasonable that they receive locoregional radiotherapy (including nodal irradiation). The role of completion mastectomy should be individualized and based on such factors as response to chemotherapy and radiotherapy, absence of metastases on re-staging examinations and patient fitness.
Patients who are treated primarily with radiotherapy should be given tumouricidal doses to areas of bulk disease (60) (61) (62) (63) (64) (65) (66) 
How is LABC treated?
The treatment of LABC is complex and must be tailored to the individual. Patients will often need a combination of therapies (called combined modality treatment), which includes:
• Chemotherapy (treatment with anticancer drugs) • Radiotherapy (treatment with high-energy x-rays) • A mastectomy (surgery that removes all breast tissue) • Hormonal therapy (treatment with the drug tamoxifen) Usually 3 cancer specialists -a surgeon, a medical oncologist and a radiation oncologist -will work together to choose and schedule the best combined modality treatment for you.
What more can I learn about LABC from this guide?
This guide summarizes a list of recommendations for treating patients with LABC. The recommendations have been written with the use of a treatment framework based on whether or not surgery is possible for the patient with newly diagnosed LABC. In other words, is the tumour operable (it can be removed completely in an operation) or is it inoperable (it cannot be removed completely)? Inoperable tumours are either:
• attached to the chest wall or skin, or • inflammatory, or • have lymph nodes attached to structures in the armpit, or have spread to a lymph node above the collarbone.
I have an operable tumour…
Will I be offered chemotherapy?
Yes, you will probably be offered chemotherapy unless your general health indicates that you would not tolerate it well. In general, the chemotherapy should include anthracyclines (anticancer agents such as doxorubicin and epirubicin). You will most likely have 6 months of chemotherapy (see guideline 8) -scheduled in 1 of 2 ways:
• Anticancer drugs will be given before surgery to shrink the tumour and make surgery easier, or • Surgery will be done first and then anticancer drugs will be given to try to destroy any remaining cancer cells. You will need to discuss with your doctor which approach will be used. You will also need to see if your health and level of fitness allow you to have chemotherapy.
Will I be offered radiotherapy?
Yes, you will probably be offered radiotherapy. This is usually scheduled after surgery and chemotherapy. The radiation will be directed at your chest wall and at the lymph nodes in your armpit and above your collarbone.
Will I be offered hormonal therapy?
Yes, if you have a tumour that is identified as one that is likely to respond to hormones. In that case, your doctor will probably recommend that you take tamoxifen (a drug that blocks the effect of estrogens) for 5 years after you finish the chemotherapy and radiotherapy, to decrease the chance of the cancer returning. Women who may not tolerate chemotherapy may be offered tamoxifen instead.
I have an inoperable tumour…
Yes, you will probably be offered chemotherapy that includes anthracyclines (anticancer agents such as doxorubicin and epirubicin). If anthracyline-based chemotherapy does not help, you may then be offered taxane-based chemotherapy (anticancer agents such as paclitaxel and docetaxel). If your cancer responds well to a particular kind of chemotherapy, you will have 4 to 6 months of treatment (see guideline 8). The way your cancer responds to the anticancer drugs will determine what treatment you receive next. For example, if the anticancer drugs make the tumour disappear, you may be offered surgery before radiotherapy. If the anticancer drugs have less effect, your physician will probably suggest radiotherapy before considering surgery. Your medical specialists will also need to consider other treatment options if your health and level of fitness do not allow you to have chemotherapy.
Yes, you will probably be offered radiotherapy. If your cancer responds to chemotherapy, you may be offered surgery with radiotherapy to follow. If your cancer responds less well to chemotherapy or you are not able to have chemotherapy, you will probably be offered radiotherapy first. At whatever point you receive radiotherapy, the radiation will be directed at your chest wall and at the lymph nodes in your armpit and above your collarbone.
